By Staff
For over forty years, I have walked into doctors' offices carrying a number that makes them reach for their prescription pads before I've even sat down. My cholesterol has hovered around 250 for as long as I can remember. It runs in the family. My aunt clocked over 400 and lived to 93 with her mind sharp and her heart still beating. The doctors have been trying to put me on statins since the first Bush administration and the one time I gave in, my body let me know in no uncertain terms that those drugs and I were not going to get along.
I am 76 years old now. I have no plaque buildup in my vessels. No stents. No bypass surgery. Just a number on a lab report that has been scaring physicians for four decades while my arteries have apparently failed to get the memo.
For the past few years, I have been hearing something I never thought I would hear from the medical world. Maybe the drugs are not the right move for everyone. Maybe a cholesterol number, in isolation, tells you about as much about heart disease risk as your shoe size. Maybe the context of metabolic health, inflammation, triglycerides, insulin sensitivity, and family history matters more than a single biomarker that the pharmaceutical industry has spent billions convincing us is the enemy.
I have been living proof of that possibility for 76 years. It is about time the science started catching up.
Dave Feldman was supposed to be a heart attack waiting to happen. His doctors told him so. His bloodwork screamed it. Instead, he may have cracked open the biggest medical mystery in a generation.
In 2015, Dave Feldman was a software engineer who had just reversed his prediabetes by cutting carbohydrates from his diet. He was lean, energetic, and by every subjective measure, healthier than he had been in years. Then his lipid panel came back. His LDL cholesterol had shot past 300. His doctors reacted with alarm, then urgency, then something approaching panic. Statins were prescribed. Warnings were issued. The message was unambiguous: his arteries were clogging by the day.
Feldman did not take the statins. He did something far more dangerous to the medical establishment. He started asking questions.
Eight years later, that decision has spawned a citizen science movement, a series of peer reviewed publications in top cardiology journals, and a growing body of gold standard coronary imaging data that directly contradicts what physicians have been taught about cholesterol for half a century.
Feldman approached his own cholesterol the way an engineer approaches a malfunctioning system. He gathered data. He isolated variables. He ran experiments on himself that would make an institutional review board wince.
His most famous demonstration became known as the "cholesterol drop experiment." By dramatically increasing his fat intake over just three days, Feldman could crash his own LDL by hundreds of points. Then, by pulling back on fat, he could send it soaring again within the same week. This should not be possible under the standard model. Cholesterol is supposed to move slowly, responding to diet over weeks and months, not days. Yet Feldman was making his LDL numbers dance on command.
The implications were unsettling. If LDL could fluctuate this wildly in response to short term energy availability, maybe it was not simply a garbage molecule accumulating in arteries. Maybe it was doing something functional. Maybe, in certain metabolically healthy people, it was a feature rather than a bug.
Feldman was not alone. Thousands of people who adopted low carbohydrate or ketogenic diets were reporting the same pattern: dramatic LDL elevations paired with excellent metabolic markers. High HDL. Very low triglycerides. Low fasting insulin. Normal blood pressure. Healthy body weight. And LDL numbers that would terrify any doctor trained in the last fifty years.
Feldman gave this pattern a name: the Lean Mass Hyper Responder, or LMHR. The defining triad was LDL cholesterol above 200 mg/dL, HDL above 80, and triglycerides below 70. These were not sick people. They were some of the metabolically healthiest individuals on the planet. And their cholesterol panels looked like a medical emergency.
The question was obvious. Were these people walking around with arteries full of plaque, oblivious to the heart attack brewing inside them? Or had the entire medical profession been measuring the wrong thing in the wrong people?
Answering this question required looking directly at coronary arteries. Not guessing from blood lipids. Not estimating risk from population equations. Actual imaging.
Feldman partnered with Dr. Matthew Budoff, a cardiologist at UCLA and one of the world's foremost experts in coronary CT angiography. Budoff is not a low carb evangelist. He is an imaging researcher who has spent his career quantifying atherosclerosis. He agreed to run the scans and let the data speak.
The study design was simple and devastating. Take 80 people who fit the LMHR or near LMHR profile: LDL above 190 mg/dL, HDL above 60, triglycerides below 80, metabolically healthy, no familial hypercholesterolemia, average of nearly five years on a ketogenic diet, mean LDL of 272 mg/dL with some participants exceeding 500. Match them one to one with controls from the Miami Heart cohort who had an average LDL of 123 mg/dL. Then perform coronary CT angiography on everyone and compare the plaque.
If the cholesterol hypothesis were correct, the keto group should have been riddled with atherosclerosis. Their LDL was 149 points higher on average. They had been marinating in it for years. By every conventional risk calculator, they were ticking time bombs.
The results landed in 2024, published in JACC: Advances, a journal of the American College of Cardiology. The median coronary artery calcium score in the keto group was zero. The median total plaque score was zero. The median stenosis score was zero. The median segment involvement score was zero. Across every imaging metric, the keto group showed no more plaque than the controls with drastically lower LDL. In the strict LMHR subset, the numbers were even more striking: both groups had median scores of zero on everything.
There was no correlation between LDL cholesterol level and plaque burden. Not a weak correlation. Not a trend. Zero.
A cross sectional snapshot is one thing. What happens over time is another. The same research team followed 100 LMHR participants for a full year with repeat CCTA scans. The results were published in early 2026.
After twelve months of sustained LDL elevation with a mean of 242 mg/dL and ApoB averaging 180 mg/dL, most participants remained in low risk territory. More than half still had a coronary calcium score of zero. Nearly four out of five had percent atheroma volume below the high risk threshold. More than nine out of ten had total plaque volume below the high risk threshold.
Fifteen percent of participants showed actual plaque regression. Their arteries got cleaner while their LDL stayed sky high.
And the most damning finding for the conventional model: neither ApoB levels nor cumulative lifetime LDL exposure predicted who developed plaque. What did predict progression was baseline plaque itself. If your arteries were clean when you started, they stayed clean. If you already had some disease, it progressed modestly. The lipid numbers floating in your blood had nothing to do with it.
Bayesian analysis found the data six to ten times more likely under the null hypothesis than under the hypothesis that ApoB drives plaque progression in this population.
None of this makes sense if you think of LDL cholesterol as a passive toxin that accumulates in arterial walls whenever concentrations get too high. But Feldman and his collaborators, particularly Oxford trained researcher Dr. Nicholas Norwitz, have proposed an alternative framework called the Lipid Energy Model.
The idea is straightforward. In a person running on fat rather than glucose, the liver packages triglycerides into VLDL particles and ships them out to tissues that need energy. Those VLDL particles offload their triglyceride cargo and become LDL particles. The LDL is not a metabolic waste product in this context. It is the return leg of an energy delivery shuttle. The more fat you burn, the more shuttles you need. The leaner and more insulin sensitive you are, the more efficiently this system runs.
This explains why LDL rises dramatically in lean metabolically healthy people on carb restricted diets but not in people carrying excess body fat. It explains why adding carbohydrates back into the diet, even in the form of Oreo cookies, can crash LDL by hundreds of points within days. It explains why these enormous LDL elevations do not translate into arterial plaque. And it makes specific, falsifiable predictions, which is what separates a scientific hypothesis from a just so story.
The cholesterol hypothesis, also called the lipid hypothesis, has been the dominant paradigm in cardiology since the Framingham Heart Study first reported associations between blood cholesterol and heart disease in the 1960s. It holds that dietary saturated fat raises blood cholesterol, which infiltrates arterial walls, which causes atherosclerosis, which causes heart attacks. Lower the cholesterol, lower the risk. This logic generated the statin industry, the low fat dietary guidelines, and a multibillion dollar war on a single molecule.
The LMHR data does not disprove every aspect of this framework. Statins do reduce cardiovascular events in secondary prevention. People with genetic familial hypercholesterolemia do develop aggressive early heart disease. But the LMHR phenomenon exposes a gaping hole in the theory. If LDL were a straightforward linear toxin, then people with LDL above 270 for years should have more plaque than people with LDL of 123. They do not. If ApoB were the master driver of atherosclerosis, then ApoB levels should predict plaque progression. In this population, they do not.
What distinguishes the LMHR is not their LDL. It is their metabolic health. Low insulin. Low inflammation. Normal blood pressure. Low triglycerides. High HDL. When the entire metabolic milieu is healthy, high LDL appears to be benign. When metabolic health deteriorates, LDL may become a problem. The particle is the same. The context is everything.
This is not a fringe idea anymore. It is published in major cardiology journals with data from the same gold standard imaging techniques used to validate the drugs that treat heart disease.
The response from mainstream cardiology has been cautious to the point of paralysis. The 2024 UK Biobank paper that reported higher cardiovascular event rates in self identified low carb dieters was widely covered in the press, despite relying on a single 24 hour dietary recall with no verification of sustained carbohydrate restriction and no metabolic phenotyping of participants. Meanwhile, the KETO trial, with its direct coronary imaging in a carefully characterized population, received a fraction of the attention.
This is how paradigm shifts are delayed. Weak observational data that supports the existing model gets amplified. Strong experimental data that challenges it gets ignored or dismissed as preliminary. The revolving door between the statin manufacturers and the guideline committees does not help. Neither does the fact that an entire generation of cardiologists built their careers on the cholesterol hypothesis and face a choice between updating their beliefs or defending their legacies.
Feldman represents something the medical establishment has never known how to handle. He has no MD. He has no PhD. He is a software engineer who looked at his own bloodwork, noticed patterns that made no sense under the standard model, and refused to accept the hand waving explanations he was given. He built a website. He collected data from thousands of strangers on the internet. He crowdfunded a clinical study. He got it published in a top journal. He forced the conversation.
The system is not designed for people like Dave Feldman. It is designed for people who wait their turn, respect the hierarchy, and do not challenge the premises their entire field is built on. Feldman did none of those things. And the data is on his side.
The KETO trial data will not end the debate overnight. Paradigm shifts in medicine take decades, not years. The statin guidelines will not be rewritten tomorrow. Doctors will continue to panic at LDL numbers above 190 and reach for their prescription pads.
But the cracks are widening. The LMHR phenotype is now a recognized entity in the medical literature. The Lipid Energy Model provides a mechanistic framework that can be tested, refined, or falsified. The coronary imaging data is public and unambiguous. Researchers who once dismissed Feldman as an internet crank are now citing his papers.
For the millions of people on low carbohydrate diets who have been told their cholesterol numbers mean they are killing themselves, the message is becoming clearer. Metabolic context matters. A lean, insulin sensitive person with high HDL, low triglycerides, and an LDL of 300 is not the same as an obese, insulin resistant person with the same LDL number. Treating them identically is not precision medicine. It is not even competent medicine. It is treating a lab value instead of a human being.
Dave Feldman set out to understand his own cholesterol. He ended up exposing the intellectual fragility of a medical dogma that has shaped dietary guidelines, drug prescriptions, and public health policy for half a century. Not bad for a guy who just wanted to know why his numbers looked weird.
Watch Here: The Cholesterol Code (2026) https://www.youtube.com/watch?v=57Z8bUb1P94
